Indoleamine 2, 3-dioxygenase (IDO) is the first and rate limiting catabolic enzyme in the
degradation pathway of the essential amino acid tryptophan. By cleaving the aromatic indole …

IDO1 (indoleamine 2, 3-dioxygenase 1) is a member of a unique class of mammalian haem
dioxygenases that catalyse the oxidative catabolism of the least-abundant essential amino …

Abstract Indoleamine 2, 3-dioxygenase (IDO) catalyzes the initial and rate‑limiting step in the
degradation pathway of the essential amino acid tryptophan and is expressed by …

The aim of this study was to confirm the existence of volatile organic compounds (VOC)
specifically released or consumed by the lung cancer cell line A549, which could be used in …

This article covers what is currently known about the role of the enzyme indoleamine 2, 3-
dioxygenase (IDO) in cancer-related immunosuppression and the clinical research on IDO …

Kidney diseases have become one of the most common health care problems. Due to a
growing number of advanced aged patients with concomitant disorders the prevalence of …

Background Adults with chronic kidney disease (CKD) exhibit alterations in tryptophan
metabolism, mainly via the kynurenine pathway, due to higher enzymatic activity induced …

Amongst the numerous mediators contributing towards the escape of tumors from the host's
immune response against them, the enzyme indoleamine 2, 3-dioxygenase (IDO) has …

Premature aging causes morphological and functional changes in the kidney, leading to
chronic kidney disease (CKD). CKD is a global public health issue with far-reaching …

Indoleamine-2, 3-dioxygenase (IDO) is the “rate-limiting” enzyme in the kynurenine (Kyn)
pathway of the tryptophan (Trp) catabolism. By its immune-modulatory effect, IDO initiates …